News Sentiment

BIIB sentiment intelligence

Biogen Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 39 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Drug Manufacturers - General Read-through group
Latest close 200.05 Week of 12 Jun 2026
Weighted tone 56/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

79/100 classification confidence.

Company focus 39

directly relevant articles

Source quality 5

high-authority source matches

Trend context Trend active

+2.4% over one week, +3.7% over four weeks, trend active, and near fair-value range.

Latest direct headline Neutral

Biogen Inc. stock outperforms competitors despite losses on the day

Market Reaction

Balanced read

65/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 79/100 classification
One-week reaction 2.4% Price confirming higher
Trend fit Trend active 3.7% over four weeks
Fair value 4.7% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 17
Neutral 19
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 39
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
simplywall.st 6
Market source 4
AD HOC NEWS 4
MarketWatch 2
Investing.com 2
GuruFocus 2
TradingView 2
The Economic Times 2

Event Lens

What the news is about

Classified themes
Market update 20
Deals and strategy 8
Analyst action 4
Earnings 4
Regulatory and legal 3

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 39
MarketWatch Direct company coverage

Biogen Inc. stock outperforms competitors despite losses on the day

Biogen Inc. (BIIB) shares declined by 1.05% to $196.58, despite an overall positive trading day for the broader market, with the S&P 500 and Dow Jones Industrial Average both rising. The stock closed 4.56% below its 52-week high achieved on May 13th.

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 16:59
Source
MarketWatch
BioPharma Dive Direct company coverage

Biogen adds more immune drugs in $1B buyout of secretive startup Raythera

Biogen has moved to acquire the secretive startup RayThera for up to $1 billion, aiming to boost its immunology drug pipeline. RayThera, founded in 2023, has kept its specific drug targets largely under wraps, but patent filings suggest it's working on modulators for TNF activity

Tone
Positive 66/100
Event
Market update
Published
18 Jun 2026 16:07
Source
BioPharma Dive
Benzinga Direct company coverage

Biogen To Acquire RayThera For Up To $1 Billion, Expanding Immunology Pipeline

Biogen (NASDAQ: BIIB) announced its agreement to acquire private biotechnology company RayThera Inc. for up to $1 billion, intending to expand its immunology pipeline. The deal involves an upfront payment and consideration tied to future clinical and regulatory milestones, with a

Tone
Positive 64/100
Event
Deals and strategy
Published
18 Jun 2026 15:07
Source
Benzinga
The Business Journals Direct company coverage

Biogen snags San Diego biotech for $1B as immunology expansion continues

Biogen is acquiring San Diego-based biotech RayThera for up to $1 billion to expand its early-stage immunology pipeline. The Cambridge drugmaker's deal focuses on developing therapies for immune-mediated conditions. This acquisition marks a significant move for Biogen in strength

Tone
Positive 70/100
Event
Deals and strategy
Published
18 Jun 2026 14:21
Source
The Business Journals
PR Newswire Direct company coverage

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB

Pomerantz LLP is investigating potential securities fraud claims against Biogen Inc. (NASDAQ: BIIB) on behalf of its investors. The investigation stems from Biogen's May 14, 2026 announcement of "topline results" from its Phase 2 CELIA study for an Alzheimer's drug, diranersen, w

Tone
Negative 18/100
Event
Regulatory and legal
Published
18 Jun 2026 14:07
Source
PR Newswire
Pharmaceutical Executive Direct company coverage

Biogen Enters $1 Billion Agreement to Acquire RayThera Inc.

Biogen has agreed to acquire private immunology biotech RayThera Inc. for up to $1 billion, significantly expanding its pipeline with a new class of undisclosed small molecule anti-inflammatory candidates. This strategic move aims to deepen Biogen's involvement in immunology, com

Tone
Positive 74/100
Event
Market update
Published
18 Jun 2026 13:44
Source
Pharmaceutical Executive
Quartz Direct company coverage

Biogen acquires RayThera in deal worth up to $1 billion

Biogen has announced the acquisition of RayThera in a deal potentially valued at up to $1 billion. This strategic move aims to expand Biogen's portfolio and capabilities. The specific therapeutic areas or technologies RayThera brings to Biogen were not detailed in the provided co

Tone
Positive 68/100
Event
Deals and strategy
Published
18 Jun 2026 13:44
Source
Quartz
Market source Direct company coverage

Biogen to Strengthen Immunology Pipeline With $1B RayThera Buyout

Biogen (BIIB) is set to acquire RayThera Inc. for up to $1 billion, a move designed to bolster its immunology pipeline with anti-inflammatory candidates currently in early-stage development. This acquisition is part of a broader trend of increased merger and acquisition activity

Tone
Positive 72/100
Event
Deals and strategy
Published
18 Jun 2026 13:37
Source
Market source
Contract Pharma Direct company coverage

Biogen Agrees to Acquire RayThera for Up to $1B

Biogen Inc. has announced its agreement to acquire RayThera Inc., a private biotechnology company specializing in small molecule therapies for immunology, for up to $1 billion. The acquisition includes an upfront payment and additional payments contingent on achieving future clin

Tone
Positive 81/100
Event
Deals and strategy
Published
18 Jun 2026 12:54
Source
Contract Pharma
Investing.com Direct company coverage

Needham reiterates Buy on Biogen stock after RayThera acquisition

Needham has reiterated a Buy rating and a $255.00 price target on Biogen Inc. following its acquisition of RayThera. The acquisition, valued up to $1 billion, brings in multiple anti-inflammatory assets to bolster Biogen's immunology pipeline, with the lead candidate expected to

Tone
Positive 73/100
Event
Deals and strategy
Published
18 Jun 2026 12:08
Source
Investing.com
marketscreener.com Direct company coverage

Morgan Stanley Raises Price Target on Biogen to $224 From $206, Keeps Equalweight Rating

Morgan Stanley has increased its price target for Biogen (BIIB) to $224 from $206, while maintaining an "Equalweight" rating on the stock. This update comes as Biogen recently announced its intention to acquire RayThera in a deal valued up to $1 billion to enhance its immunology

Tone
Positive 65/100
Event
Analyst action
Published
18 Jun 2026 10:37
Source
marketscreener.com
ACCESS Newswire Direct company coverage

Biogen Inc. (BIIB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of Biogen Inc. (BIIB) investors after the company announced that its Phase 2 CELIA study for diranersen failed to meet primary endpoints, causing a 6.4% stock price drop. The firm encourages investors

Tone
Negative 28/100
Event
Regulatory and legal
Published
18 Jun 2026 01:37
Source
ACCESS Newswire